News & Events

Press Releases

On the 28th March 2022, OncoArendi changed its name to Molecure

OncoArendi Therapeutics Reports Continued Strategic and Operational Momentum for 12 Months ended 31 December 2021

25 March 2022

OncoArendi Therapeutics Announces a License Option Agreement with University of Michigan

11 March 2022

OncoArendi Therapeutics Appoints Dr. Adam Gołębiowski, Dr. Zbigniew Zasłona and Agnieszka Rajczuk-Szczepańska to its Management Board  

31 January 2022

OncoArendi Therapeutics Appoints Samson Fung, M.D. as Chief Medical Officer

27 January 2022

OncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts: Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński as its new members

14 January 2022

OncoArendi continues to grow by executing further steps of the strategy and initiates two new drug discovery programs within its existing research platforms

19 August 2021

Events & Presentations

R&D Day Presentation, 07.12.2022

7 December 2022

Fibrosis and Tissue Repair: From Molecules and Mechanics to Therapeutic Approaches – February 19-23, 2020 | Victoria, BC, Canada

27 February 2020

EFMC-ASMC’19 – September 1-5, 2019 | Athens, Greece

11 September 2019

ACS National Meeting & Expo – August 25 – 29, 2019 | San Diego, CA

4 September 2019

ATS- International Conference – Dallas, 17-22.05.2019

22 May 2019

EFMC – YMCS – Young Medicinal Chemist Symposium – Ljubljana 02-06.09.2018

17 September 2018
This site is registered on wpml.org as a development site.